UCB, Novartis To Co-Develop Two Alpha Synuclein Modulators for Parkinson’s

UCB and Novartis have joined forces in what could be a $1.5 billion deal to develop two investigational molecules targeting alpha synuclein, the misfolded protein involved in Parkinson’s disease.
Source: Drug Industry Daily